Cencora, Inc. COR
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE
Revenue
$262.17B
+9.9% YoY
Net income
$1.75B
+2.7% YoY
Total assets
$67.10B
+7.3% YoY
EPS
8.53
+6.1% YoY
Advertisement
Income Statement
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $237.60B | $156.94B | $81.49B | $262.17B | $214.91B | $140.67B | $72.25B | $238.59B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | $8.52B | $5.62B | $2.56B | $8.96B | $7.42B | $5.01B | $2.47B | $8.30B |
| SG&A Expense | $4.74B | $3.07B | $1.47B | $5.31B | $4.17B | $2.79B | $1.40B | $4.85B |
| Operating Income (Loss) | $2.61B | $1.74B | $706.25M | $2.34B | $2.05B | $1.38B | $822.88M | $2.37B |
| Net Income (Loss) | $1.89B | $1.21B | $488.60M | $1.75B | $1.51B | $1.02B | $601.50M | $1.70B |
| EPS (Diluted) | 9.70 | 6.18 | 2.50 | 8.53 | 7.49 | 5.07 | 2.98 | 8.04 |
Balance Sheet
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $76.59B | $76.59B | $76.59B | $67.10B | $67.10B | $67.10B | $67.10B | $62.56B |
| Current Assets | $52.24B | $52.24B | $52.24B | $47.72B | $47.72B | $47.72B | $47.72B | $42.80B |
| Cash & Equivalents | $3.13B | $3.13B | $3.13B | $3.39B | $2.59B | $2.59B | $2.59B | $2.55B |
| Accounts Receivable | $25.23B | $25.23B | $25.23B | $23.87B | $23.87B | $23.87B | $23.87B | $20.91B |
| Inventory | $20.49B | $20.49B | $20.49B | $19.00B | $19.00B | $19.00B | $19.00B | $17.45B |
| PP&E (Net) | $2.54B | $2.54B | $2.54B | $2.18B | $2.18B | $2.18B | $2.18B | $2.14B |
| Goodwill | $13.68B | $13.68B | $13.68B | $9.57B | $9.32B | $9.32B | $9.32B | $8.50B |
| Current Liabilities | $57.82B | $57.82B | $57.82B | $54.28B | $54.28B | $54.28B | $54.28B | $48.83B |
| Accounts Payable | $54.72B | $54.72B | $54.72B | $50.94B | $50.94B | $50.94B | $50.94B | $45.84B |
| Long-Term Debt | $7.66B | $7.66B | $7.66B | $4.39B | $4.39B | $4.39B | $4.39B | $4.79B |
| Stockholders Equity | $1.51B | $1.51B | $1.51B | $645.94M | $645.94M | $645.94M | $645.94M | $522.00M |
Cash Flow Statement
| Period | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $741.70M | $632.46M | $-2.72B | $3.91B | $2.48B | $6.71M | $885.16M | $2.70B |
| Investing Cash Flow | $-4.66B | $-4.42B | $-343.04M | $-2.60B | $-376.21M | $-232.29M | $-65.80M | $-368.44M |
| Financing Cash Flow | $2.93B | $2.72B | $3.21B | $-2.22B | $-1.37B | $-228.50M | $-551.67M | $-1.75B |
| Stock Repurchases | — | — | — | $1.18B | $435.40M | $435.40M | $385.40M | $483.70M |
Similar companies
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.